Search Hematology Advisor's extensive coverage of leukemia focused content. Breaking news about leukemia research developments and treatment plans are updated frequently.
LEUKEMIA

Feature

Expert Perspective: The Role of Ibrutinib and Venetoclax in Chronic Lymphocytic Leukemia

Hematology Advisor asked Prithviraj Bose, MD, to discuss the latest research on treatment options for CLL presented at the ASH 2018 Annual Meeting.

Latest News

Exploring the Prognostic Value of Minimal Residual Disease From Peripheral Blood in Pediatric ALL

By

Minimal residual disease from peripheral blood, which is easier to obtain than bone marrow, was found to correlate with some clinical outcomes.

Ponatinib as a Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

By

Patients receiving ponatinib in combination with other therapeutic agents appeared to achieve sustained responses and long-term remission.

Sprycel Plus Chemotherapy OK'd to Treat Certain Pediatric Patients With Ph+ ALL

By

The expanded approval was supported by data from the Phase 2 multicenter, single-arm CA180-372 study (NCT01460160) which included 78 pediatric patients with newly diagnosed B-cell precursor Ph+ ALL.

Two Mutations Prognostic of Survival in Acute Myeloid Leukemia Regardless of Hematopoietic Stem Cell Transplantation

By

Internal tandem duplications in FLT3 and mutations in CEBPA were independently prognostic of overall survival in patients with acute myeloid leukemia.

Outcomes of Induction Chemotherapy for Acute Myeloid Leukemia With Multilineage Dysplasia

By

Results of a study on the influence of induction chemotherapy on transplant outcomes for patients with acute myeloid leukemia.

Efficacy of Ibrutinib, Rituximab, and Bendamustine in Untreated CLL

By

Results of a phase 3 trial of efficacy that used progression-free survival as its primary endpoint.

Assessing Measurable Residual Disease in Patients With Acute Lymphoblastic Leukemia

By

Measurable residual disease status can inform treatment for patients with ALL, but the optimal methods for assessment and interpretation are unclear.

Azacitidine May Prevent Relapse in Patients With Measurable Residual Disease

By

Researchers evaluated the proportion of patients who had not experienced relapse at 6 months after initiation of azacitidine treatment.

Induction Chemotherapy Is Well Tolerated in Elderly Patients With Acute Myeloid Leukemia

By

The researchers reported more than 75% of patients achieved complete response after 1 cycle of the intensive chemotherapy regimen.

Phase 2 Trial of 3 Novel Regimens for Relapsed/Refractory Acute Myeloid Leukemia

By

A combination of alvocidib, cytarabine, and mitoxantron was found to outperform other novel treatments for relapsed/refractory acute myeloid leukemia.

FDA: Serious Side Effect of AML Drug Not Being Recognized

By Steve Duffy

From May 1 2018 to July 31 2018, 5 cases of death associated with DS in patients taking Idhifa have been reported; in 2 of these cases, DS was listed as the only cause of death.

Bone Marrow Core Biopsy May Be Beneficial in Workup for Chronic Myeloid Leukemia

By

Researchers retrospectively analyzed data from 508 patients with chronic myeloid leukemia who had received bone marrow aspiration or core biopsy.

Participation in Clinical Studies May Be Linked to Higher Remission Rates

By

Complete remission rates were higher for newly diagnosed patients on study compared with newly diagnosed patients off study.

Inotuzumab Ozogamicin May Be Efficacious and Safe in Relapsed Pediatric Acute Lymphoblastic Leukemia

By

The efficacy of inotuzumab ozogamicin in pediatric patients is less understood than in adult patients.

Relapse in Acute Myeloid Leukemia and Dysregulation of Immune Genetic Pathways

By

One of the effects of immune pathway dysregulation was decreased antigen presentation by MHC Class II genes.

The Price Is Right for CAR-T in Pediatric Patients, Analysis Concludes

By Christina Bennett, MS

For children with relapsed or refractory B-cell acute lymphoblastic leukemia, tisagenlecleucel was deemed cost-effective, yet long-term outcomes are still uncertain.

Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML

By Christina Bennett, MS

For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.

Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia

By Randi Hernandez

Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.

Too Much Physical Activity During Therapy for Pediatric ALL Decreases Cognitive Function

By James Nam, PharmD

Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.

Harnessing the Power of Both Alemtuzumab and Rituximab in a Bispecific Antibody

By Randi Hernandez

Researchers hypothesized that a combination bispecific mAb in B-cell malignancies could offer a treatment option superior to existing monospecific mAbs.

SIGN UP FOR FREE E-NEWSLETTERS